Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade

INTRODUCTION: Checkpoint inhibitors have improved outcomes in metastatic melanoma, with 4-year overall survival (OS) of 46% for anti-PD-1 alone or 53% in combination with anti-CTLA-4. However, the median progression free survival is 6.9 and 11.5 months, respectively. Many who progress have gone on t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Surg Oncol
Main Authors: Bello, Danielle M., Panageas, Katherine S., Hollmann, Travis, Shoushtari, Alexander N., Momtaz, Parisa, Chapman, Paul B., Postow, Michael A., Callahan, Margaret K., Wolchok, Jedd D., Brady, Mary S., Coit, Daniel G., Ariyan, Charlotte E.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7112166/
https://ncbi.nlm.nih.gov/pubmed/31848819
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1245/s10434-019-08099-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados